ReviewVaccine: X2024
Human papilloma virus vaccination in the resource-limited settings of sub-Saharan Africa: Challenges and recommendations.
Review in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Determinants of human papillomavirus vaccination uptake in Nigeria: a mixed-methods systematic review.BMC public health · 2026Pooled it
- Acceptance of HPV Vaccination: A Systematic Review of Knowledge, Attitudes and Barriers Among Healthcare Practitioners in Low- and Middle-Income Countries.BioMed research international · 2026Pooled it
- Financing of Human Papillomavirus Vaccination in Africa: A Scoping Review.Health science reports · 2026Review
- Preliminary Development and Assessment of a Multiplex Assay for Human Papillomavirus Antibody Detection Using Commercial L1 Proteins.Journal of clinical laboratory analysis · 2026Article
- Potential Impact of Catch-Up HPV Vaccination on HPV Prevalence and Cervical Cancer Incidence Among Women Living With HIV in South Africa: Results From Two Mathematical Models.Journal of the International AIDS Society · 2026Article
- Association of the HPV vaccination intention‒behavior gap with ehealth literacy and health beliefs among chinese female college students: cross-sectional study.Scientific reports · 2026Article
- Preclinical evaluation of high-dose Griffithsin carrageenan fast-dissolving insert for HIV, HSV-2, and HPV prevention.Microbiology spectrum · 2026Article
- From campaign to continuity: stakeholders' recommendations for integrating HPV vaccination into Nigeria's healthcare system.BMC health services research · 2026Article
- Gaps and barriers preventing sustained delivery of HPV vaccination in Kano, Kaduna, and Lagos states: An exploratory qualitative study.PloS one · 2026Article
- Marginalized voices on HPV vaccination in India: exploring knowledge, attitudes, and acceptance.Frontiers in global women's health · 2026Article
- Article
- Initial Coverage and Regional Disparities of the National HPV Vaccination Program in Poland: A Cross-Sectional Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Human Papillomavirus (HPV) Vaccination and Cervical Cancer Prevention: Ghanaian Adolescent Students' Perspectives Through Focus Group Discussion.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Article
- Advances in human papillomavirus detection for cervical cancer screening and diagnosis: challenges of conventional methods and opportunities for emergent tools.Analytical methods : advancing methods and applications · 2025Review
- Gender-neutral human papillomavirus vaccination: an equitable and cost-effective public health investment.Frontiers in public health · 2025Article
- Knowledge and attitudes of medical students regarding human papilloma virus infection and vaccine: cross-sectional study from Jordan.Frontiers in cellular and infection microbiology · 2025Article
- Determinants of cervical cancer knowledge and barriers to human papillomavirus vaccine uptake among female university students: A cross-sectional study.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human papillomaviruses (HPV) cause 99% of all cervical cancer cases globally, with the high-risk genotypes 16 and 18 causing at least 70% of these cases. An estimated 90% of the global cervical cancer burden occurs in low-to-middle-income countries (LMICs), particularly in sub-Saharan Africa (SSA). Primary prevention through the administration of efficacious HPV vaccines is key to the World Health Organization's global strategy for accelerating the elimination of cervical cancer as a disease of public health concern. The rollout of HPV vaccination in SSA is faced with several challenges, such as the high cost of vaccine procurement, a lack of funding and political will from the central governments of countries, and inadequate infrastructure for vaccine cold chain storage and transport. Stigma, misinformation, lack of education and awareness, and vaccine hesitancy constitute the social factors that affect the successful rollout or implementation of vaccination programs in SSA. Based on the challenges SSA faces in rolling out HPV vaccination, we recommend using strategies that address both the demand-side and supply-side obstacles to HPV vaccination uptake. These include costs and availability, fighting vaccine hesitancy, and increasing vaccine confidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.